lovastatin has been researched along with Multiple Myeloma in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 9 (64.29) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allen, C; Born, EJ; Holstein, SA; Wiemer, DF; Zhou, X | 1 |
| Hohl, RJ; Holstein, SA | 1 |
| Adamczyk-Cioch, M; Dmoszynska, A; Grzasko, N; Helbig, G; Hus, M; Jawniak, D; Kozinska, J; Legiec, W; Morawska, M; Pluta, A; Szostek, M; Waciński, P; Woszczyk, D | 1 |
| Bloem, AC; Kamphuis, MM; Lokhorst, HM; van de Donk, NW; van Kessel, B | 1 |
| Dong, ZR; Du, XY; Liu, ZL; Luo, JM; Wang, FX; Yang, JC; Yao, L; Zhang, XJ | 1 |
| Barna, G; Bocsi, J; Jánosi, J; Kopper, L; Nagy, K; Sebestyén, A; Vályi-Nagy, I | 1 |
| Chng, WJ; Lau, LG; Mow, BM; Yusof, N | 1 |
| Aydilek, E; Ganser, A; Morgan, MA; Peest, D; Reuter, CW; Sebil, T | 1 |
| Dmoszynska, A; Grzasko, N; Klimek, P; Podhorecka, M | 1 |
| Ebetino, FH; Edwards, CM; Hulley, PA; Roelofs, AJ; Rogers, MJ; Russell, RG | 1 |
| Bergsagel, PL; Boutros, PC; Bros, C; Clendening, JW; Jurisica, I; Khosravi, F; Martirosyan, A; Penn, LZ; Stewart, AK; Wong, WW | 1 |
| Bertieri, R; Boccarelli, A; Cirulli, T; Coluccia, AM; Coluccia, M; Dammacco, F; Di Pietro, G; Giannini, T; Mangialardi, G; Ribatti, D; Scavelli, C; Vacca, A | 1 |
| Holmberg, M; Larsson, R; Nygren, P; Sandberg, C | 1 |
| Croucher, PI; Helfrich, MH; Rogers, MJ; Russell, RG; Shipman, CM | 1 |
1 review(s) available for lovastatin and Multiple Myeloma
| Article | Year |
|---|---|
Targeted therapy in multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; DNA, Antisense; Drug Delivery Systems; Farnesyltranstransferase; Humans; Immunosuppressive Agents; Lovastatin; Multiple Myeloma; Oxides; Protease Inhibitors; Pyrazines; Thalidomide | 2005 |
1 trial(s) available for lovastatin and Multiple Myeloma
| Article | Year |
|---|---|
Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunomodulation; Immunosuppressive Agents; Lovastatin; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Salvage Therapy; Stem Cell Transplantation; Survival Analysis; Thalidomide; Transplantation, Autologous | 2011 |
12 other study(ies) available for lovastatin and Multiple Myeloma
| Article | Year |
|---|---|
N-Oxide derivatives of 3-(3-pyridyl)-2-phosphonopropanoic acids as potential inhibitors of Rab geranylgeranylation.
Topics: Alkyl and Aryl Transferases; Cell Line, Tumor; Drug Discovery; Humans; Molecular Structure; Multiple Myeloma; Propionates; Structure-Activity Relationship | 2015 |
Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells.
Topics: Apoptosis; Biosynthetic Pathways; Cell Line, Tumor; Diphosphonates; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Immunoblotting; Immunoglobulin lambda-Chains; Immunoglobulin Light Chains; Lovastatin; Multiple Myeloma; Prenylation; rab1 GTP-Binding Proteins; Reverse Transcriptase Polymerase Chain Reaction; Terpenes; Tunicamycin; Unfolded Protein Response; Zoledronic Acid | 2011 |
Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels.
Topics: Alkyl and Aryl Transferases; Apoptosis; Bone Marrow Cells; Cell Line, Tumor; Diterpenes; Down-Regulation; Drug Antagonism; Enzyme Inhibitors; Humans; Lovastatin; Mitochondria; Mitochondrial Proteins; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Protein Prenylation; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2003 |
[In vitro effects of mevastatin on the proliferation and apoptosis in human multiple myeloma cell line U266].
Topics: Apoptosis; Cell Division; Cell Line, Tumor; G1 Phase; Genes, bcl-2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Multiple Myeloma | 2004 |
[Mevastatin induced apoptosis in U266 human myeloma cell line].
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Blotting, Western; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Membrane Glycoproteins; Multiple Myeloma; Proteoglycans; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Syndecan-1; Syndecans | 2004 |
Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
Topics: Adult; Alkyl and Aryl Transferases; Antineoplastic Agents; Apoptosis; Cell Death; Cell Division; Cell Movement; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Lovastatin; MAP Kinase Signaling System; Multiple Myeloma; Protein Prenylation; ras Proteins; Tumor Cells, Cultured | 2005 |
Lovastatin and thalidomide have a combined effect on the rate of multiple myeloma cell apoptosis in short term cell cultures.
Topics: Apoptosis; bcl-2-Associated X Protein; Drug Synergism; Drug Therapy, Combination; Humans; Kinetics; Lovastatin; Multiple Myeloma; Proto-Oncogene Proteins c-bcl-2; Thalidomide; Tumor Cells, Cultured | 2006 |
Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Diphosphonates; Down-Regulation; Drug Synergism; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mevalonic Acid; Multiple Myeloma; Phosphatidylcholines; Protein Prenylation | 2007 |
Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma.
Topics: Apoptosis; Disease Progression; GTP Phosphohydrolases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mevalonic Acid; Multiple Myeloma | 2007 |
Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma.
Topics: Adult; Aged; Base Sequence; Blotting, Western; Culture Media, Conditioned; Diphosphonates; DNA Primers; Enzyme-Linked Immunosorbent Assay; Female; Humans; Imidazoles; Lovastatin; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Phenotype; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2007 |
Effects of lovastatin on a human myeloma cell line: increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Division; Doxorubicin; Drug Resistance, Multiple; Flow Cytometry; Humans; Indicators and Reagents; Lovastatin; Multiple Myeloma; Tumor Cells, Cultured | 1994 |
The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Diphosphonates; Diterpenes; Enzyme Inhibitors; Farnesol; Humans; Lovastatin; Mevalonic Acid; Multiple Myeloma; Protein Prenylation; Tumor Cells, Cultured | 1998 |